Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2

ISBT COVID-19 Convalescent Plasma Working Group (see the Appendix)

نتاج البحث: المساهمة في مجلةمراجعة النظراء

1 اقتباس (Scopus)

ملخص

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the potential therapeutic value of early passive polyclonal immunotherapy using high-titer convalescent plasma (CCP). Human polyclonal hyperimmune immunoglobulin (HIG) has several advantages over CCP. Unlike CCP, HIG can provide standardized and controlled antibody content. It is also subjected to robust pathogen reduction rendering it virally safe and is purified by technologies demonstrated to preserve immunoglobulin neutralization capacity and Fc fragment integrity. This document provides an overview of current practices and guidance for the collection and testing of plasma rich in antibodies against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and its industrial fractionation for the manufacture of quality-assured and safe HIG. Considerations are also given to the production of HIG preparations in low- and middle-income countries.

اللغة الأصليةEnglish
دوريةTransfusion Medicine Reviews
المعرِّفات الرقمية للأشياء
حالة النشرAccepted/In press - 2022

ASJC Scopus subject areas

  • ???subjectarea.asjc.2700.2720???
  • ???subjectarea.asjc.1300.1308???
  • ???subjectarea.asjc.2700.2704???

بصمة

أدرس بدقة موضوعات البحث “Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا